AbbVie stock in focus after positive QULIPTA migraine trial
Published on 11/13/2026 at 13:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline data sharpen migraine focus
- QULIPTA showed stronger tolerability and efficacy than topiramate in the TEMPLE study.
- The result adds support to AbbVie's neuroscience pipeline as investors assess future commercial traction.
- The next test is whether the clinical advantage translates into prescriptions and revenue.
AbbVie is gaining a fresh pipeline catalyst after positive Phase 3 results for QULIPTA in migraine prevention. A Yahoo Finance report published Thursday, November 12, said the TEMPLE study produced favorable results for atogepant, marketed as QULIPTA, in a head-to-head comparison with topiramate.
QULIPTA strengthens the migraine case
The 24-week blinded phase compared the two oral treatments in adults with migraine. According to the report, 12 percent of patients receiving atogepant stopped treatment because of side effects, compared with 30 percent of those taking topiramate. The study also showed better efficacy for QULIPTA on key migraine-prevention endpoints.
The readout strengthens AbbVie's position in oral migraine prevention, where treatment persistence is commercially important. Better tolerability can support continued use, while stronger prevention results may improve the product's competitive profile. The trial outcome alone, however, does not establish future prescription growth or revenue.
Commercial execution remains next
AbbVie is using immunology and neuroscience to support growth as older products face increasing competition, the Yahoo Finance analysis said. The report highlighted QULIPTA alongside Ubrelvy as part of the company's migraine franchise and pointed to future quarterly disclosures as the next opportunity to assess commercial traction.
AbbVie stock traded at 266.70 euros on Lang & Schwarz at 1:02 p.m. CET on Friday, November 13, 2026.
AbbVie Inc.
- ISIN: US00287Y1091
- Company: AbbVie Inc.
- Primary listing: NYSE
- Current quote: 266.70 euros on Lang & Schwarz, Friday, November 13, 2026, 1:02 p.m. CET
- Clinical program: QULIPTA, or atogepant
- Trial: Phase 3 TEMPLE migraine-prevention study
The broader US market backdrop is tracked through the S&P 500.
